Australia’s first RNA vaccine candidate clinical trials start next year


The Victoria State Government has announced that Australia’s first messenger RNA (mRNA) COVID-19 vaccine candidate will begin clinical trials in the new year.

Jaala Pulford, Minister of Medical Research, Victoria said that the production of vaccine candidates has made Victoria a leader in mRNA treatment and production.

“It’s an incredible achievement to create an mRNA vaccine candidate ready for clinical trials,” he said.

Vaccine candidates were created to combat the beta COVID-19 mutant. The beta COVID-19 mutant has since disappeared, but has also begun in southern Africa.

The test will be conducted by the Doherty Institute, which provided research and modeling of Australia’s national plan to reopen the country after a pandemic.

Professor Terry Nolan, head of the Vaccine and Immunization Research Group at the Doherty Institute, said Australia is a “major milestone” in its ability to produce homemade COVID-19 mRNA vaccines.

“We are pleased to begin Phase 1 clinical trials of this candidate with a protein vaccine candidate developed by the Doherty Institute within the next few months,” he said.

Approximately 120 people between the ages of 18 and 70 who have already been vaccinated twice with COVID-19 will be invited to participate in the study.

“They must have had a second dose at least 3 months ago. They will receive either. mRNA A vaccine or another vaccine, some individuals in this study will receive a placebo, “Nolan said.

“We want everyone to do this quickly before taking the third dose. Once taken, there will be a shortage of potential volunteers.”

According to this release, RNA vaccine candidates have been created “in just five months” and have been administered 450 times in Boronia, a suburb of Melbourne, allowing 150 people to participate in Phase 1 clinical trials conducted by the Doherty Institute. rice field. Results are expected in the second half of 2022.

This project is part of a “breakthrough collaboration” led by mRNA Victoria in partnership with the Monash Institute of Pharmaceutical Sciences (MIPS), Doherty Institute, and IDT Australia.

Colin Puton, a professor of pharmaceutical biology at Monash University, said: “

Dr. David Sparling, CEO of IDT Australia, said he was honored to be involved in this project.

“We believe this product is the first locally developed mRNA COVID-19 vaccine candidate and the first locally manufactured cGMP mRNA drug,” he said.

The Victoria State Government has invested $ 5 million in dose production using dedicated equipment shipped from Canada.

The machine processed the nanoparticles into the final liquid dosage form, sterilized the product, and filled the vials with the mRNA vaccine, Release said.

The Victoria State Government has established mRNA Victoria to support Victoria’s proposal for a federal market approach to mRNA production capacity.

Caden Pearson


Caden Pearson is an Australian-based reporter with a background in screen writing and documentary. Contact him at [email protected]